Author

Cooper C

September 11, 2015
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Summary Background The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity […]

Read More
August 28, 2015
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition
Summary Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age–sex groups, and countries. The GBD can be used to generate summary measures […]

Read More
August 24, 2015
Interferon-based hepatitis C antiviral treatment outcomes may be predicted by alanine aminotransferase levels
Summary On-therapy decline or normalization of liver enzyme levels is often observed following initiation of interferon-based hepatitis C virus (HCV) antiviral treatment and may reflect response to therapy and decreasing HCV RNA levels (1,2). On-treatment alanine aminotransferase (ALT) level elevation may be associated with persistent viremia (3–5). The value of enzymatic response in predicting sustained […]

Read More
July 22, 2014
Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Summary Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in duration and simpler to administer. Coinciding with new treatment options are novel methodologies for disease screening and […]

Read More
June 8, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
Summary Background and Aim Decisions on public health issues are dependent on reliable epidemiological data. A comprehensive review of the literature was used to gather country-specific data on risk factors, prevalence, number of diagnosed individuals and genotype distribution of the hepatitis C virus (HCV) infection in selected European countries, Canada and Israel. Methodology Data references […]

Read More

Author

Cooper C

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition

Interferon-based hepatitis C antiviral treatment outcomes may be predicted by alanine aminotransferase levels

Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

Useful Links, CDAF

Useful Links, Polaris

Latest News